- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Aytu BioPharma Inc (AYTU)
The Aytu BioPharma share price today is 2.070, view NASDAQ AYTU stock exchange data. Track the latest Aytu BioPharma share price with real-time updates on AYTU stock performance including market cap, day range, 52-week range and dividend yield. Access AYTU charts, earnings dates and analyst estimates to support your investment decisions.
2.070
-0.020(-0.96%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.060
2.150
52 wk Range
1.800
3.065
AYTU is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.0602.150
52 wk Range
1.8003.065
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AYTU Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
9.667
Upside
+366.99%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 9.667
(+366.99% Upside)
Aytu BioPharma Inc Earnings Call Summary for Q4/2026
- Aytu BioPharma Q4 fiscal 2026 revenue rose 6% YoY to $16.1M, beating estimates by 31.1% at $12.28M; stock gained 9.65% through after-hours.
- Lead depression drug EXXUA revenue jumped to $3.9M from $2.4M in Q3; prescriptions more than doubled to 3,323 as commercial launch gained traction.
- Adjusted EBITDA turned positive at $0.5M vs. negative $2.8M in Q3; net loss narrowed to $0.1M from $19.8M year-earlier, nearing breakeven.
- FY2027 operating expenses guided at $49M-$54M with $6M increase in sales/marketing; gross margin expected to reach 66%-67% by Q4 fiscal 2027.
- Management projects positive adjusted EBITDA for six months ending June 2027; plans material sales force expansion above 42 reps pending cash flow.
Last Updated: 23-09-2026, 02:56 am
Read Full TranscriptEarnings
Latest Release
22-09-2026
EPS / Forecast
-- / -0.28
Revenue / Forecast
16.1M / 12.28M
Compare AYTU to Peers and Sector
Metrics to compare | AYTU | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAYTUPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | −14.8x | −0.4x | |
PEG Ratio | −0.03 | −1.29 | 0.00 | |
Price/Book | 0.7x | 1.2x | 2.6x | |
Price / LTM Sales | 0.4x | 2.4x | 3.0x | |
Upside (Analyst Target) | 362.5% | 83.7% | 56.4% | |
Fair Value Upside | Unlock | 10.8% | 7.9% | Unlock |
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Aytu BioPharma (AYTU) Share Price Today?
The Aytu BioPharma share price today is 2.070.
What is the current Aytu BioPharma (AYTU) share price and day range?
As of 02-10-2026, the Aytu BioPharma share price is 2.070, with a previous close of 2.090. The share price has ranged from 2.060 to 2.150 today, while the 52-week range spans from 1.800 to 3.065.
What Is the Aytu BioPharma Market Cap?
As of today, Aytu BioPharma market cap is 22.490M.
What Is the Aytu BioPharma (AYTU) Share Price Target?
The average 12-month share price target for Aytu BioPharma is 9.667, with a high estimate of 15 and a low estimate of 7. 3 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +366.99% Upside potential.
What Is Aytu BioPharma's Earnings Per Share (TTM)?
The Aytu BioPharma EPS (TTM) is -1.157.
When Is the Next Aytu BioPharma Earnings Date?
Aytu BioPharma will release its next earnings report on 16-11-2026.
From a Technical Analysis Perspective, Is AYTU a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Aytu BioPharma Trade On?
Aytu BioPharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Aytu BioPharma?
The stock symbol for Aytu BioPharma is "AYTU."
How Many Times Has Aytu BioPharma Stock Split?
Aytu BioPharma has split 6 times.
How Many Employees Does Aytu BioPharma Have?
Aytu BioPharma has 76 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.